NEW YORK (GenomeWeb) – Roche today announced the US Food and Drug Administration has approved the company's Cobas cytomegalovirus test for use on the fully automated Cobas 6800 and 8800 systems.

The real-time PCR-based Cobas CMV test is for assessing how transplant patients on therapy respond to treatment. It offers an expanded linear rage from 34.5 IU/mL to 1E+07 IU/mL with robust coverage across genotypes, Roche said, adding that the test minimizes variability and complexity testing, reducing workload and risk for laboratories offering laboratory-developed tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.